Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

Autor: Kalinsky, Kevin, Bianchini, Giampaolo, Hamilton, Erika P., Graff, Stephanie L., Park, Kyong Hwa, Jeselsohn, Rinath, Demirci, Umut, Martin, Miguel, Layman, Rachel M., Hurvitz, Sara A., Sammons, Sarah L, Kaufman, Peter A., Muñoz, Montserrat, Tseng, Ling-Ming, Knoderer, Holly, Nguyen, Bastien, Zhou, Yanhong, Ravenberg, Elizabeth, Litchfield, Lacey M, Wander, Seth Andrew
Zdroj: Journal of Clinical Oncology; 2024 Supplement 17, Vol. 42, pLBA1001-LBA1001, 83p
Databáze: Supplemental Index